Loading...
•
Sep 30, 2022
Black Diamond Therapeutics Q3 2022 Earnings Report
Black Diamond Therapeutics reported financial results for the third quarter ended September 30, 2022 and provided a corporate update.
Key Takeaways
Black Diamond Therapeutics reported a net loss of $21.7 million for the third quarter of 2022, with cash, cash equivalents, and investments of $144.2 million as of September 30, 2022. The company is focusing on advancing its lead programs and leveraging its MAP Drug Discovery Engine.
Presented new data at the 34th EORTC-NCI-AACR Symposium highlighting robust preclinical anti-tumor activity of BDTX-1535 and BDTX-4933.
On track to provide a clinical update on BDTX-1535 in 2023 and to file an IND for BDTX-4933 in the first half of 2023.
Melanie Morrison was appointed as Senior Vice President, Development Operations.
Cash, cash equivalents and investments of approximately $144.2 million as of September 30, 2022; expected to be sufficient to fund operations into the third quarter of 2024.
Forward Guidance
Black Diamond expects its cash runway to be sufficient to fund its anticipated operating expenses and expenditure requirements into the third quarter of 2024.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...